4.6 Article

Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

Journal

RSC ADVANCES
Volume 5, Issue 100, Pages 81817-81830

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c5ra15191k

Keywords

-

Funding

  1. National Natural Science Foundation of China [21072171, 81072575]
  2. Science and Technology Department of Zhejiang Province [2014C33181]

Ask authors/readers for more resources

Hypoxia inducible factor-1 (HIF-1) is the key transcription factor of cellular response to hypoxia and plays a critical role in tumor metastasis. We describe here the discovery and a structure-activity relationship study of a series of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives as novel HIF-1 inhibitors. The two most promising compounds 4g and 4h inhibit HIF-1 transcription with IC50 values of 0.62 and 0.55 mu M in vitro, respectively, and they exhibit more efficient HIF-1 inhibition in xenograft tumors than YC-1, a potential anticancer drug targeting HIF-1. In addition, they also remarkably prevent the hypoxia-driven migration of SKOV3 cells in vitro and tumor metastasis in vivo. Further investigation of the mechanism revealed that the two inhibitors could decrease HIF-1 alpha and VEGF expression. These results suggest that our newly synthesized HIF-1 inhibitors 4g and 4h are potential therapeutic agents with which to treat tumor metastasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

Maria R. Abbattista, Stephen M. F. Jamieson, Yongchuan Gu, Jennifer E. Nickel, Susan M. Pullen, Adam V. Patterson, William R. Wilson, Christopher P. Guise

CANCER BIOLOGY & THERAPY (2015)

Article Oncology

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Francis W. Hunter, Richard J. Young, Zvi Shalev, Ravi N. Vellanki, Jingli Wang, Yongchuan Gu, Naveen Joshi, Sreevalsan Sreebhavan, Ilan Weinreb, David P. Goldstein, Jason Moffat, Troy Ketela, Kevin R. Brown, Marianne Koritzinsky, Benjamin Solomon, Danny Rischin, William R. Wilson, Bradly G. Wouters

CANCER RESEARCH (2015)

Article Oncology

Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells

Ji Cao, Yijie Wang, Rong Dong, Guanyu Lin, Ning Zhang, Jing Wang, Nengming Lin, Yongchuan Gu, Ling Ding, Meidan Ying, Qiaojun He, Bo Yang

CANCER RESEARCH (2015)

Article Hematology

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Marina Konopleva, Peter F. Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, Sergej Konoplev, Yongchuan Gu, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah Thomas, Jorge Cortes, Tapan Kadia, Steven Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, Jennie Feliu, Hongbo Lu, Caimiao Wei, William R. Wilson, Teresa J. Melink, John C. Gutheil, Michael Andreeff, Elihu H. Estey, Hagop Kantarjian

HAEMATOLOGICA (2015)

Article Hematology

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Marina Konopleva, Peter F. Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, Sergej Konoplev, Yongchuan Gu, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah Thomas, Jorge Cortes, Tapan Kadia, Steven Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, Jennie Feliu, Hongbo Lu, Caimiao Wei, William R. Wilson, Teresa J. Melink, John C. Gutheil, Michael Andreeff, Elihu H. Estey, Hagop Kantarjian

HAEMATOLOGICA (2015)

Article Pharmacology & Pharmacy

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

Yongchuan Gu, Tony T. -A. Chang, Jingli Wang, Jagdish K. Jaiswal, David Edwards, Noel J. Downes, H. D. Sarath Liyanage, Courtney R. H. Lynch, Frederik B. Pruijn, Anthony J. R. Hickey, Michael P. Hay, William R. Wilson, Kevin O. Hicks

FRONTIERS IN PHARMACOLOGY (2017)

Article Pharmacology & Pharmacy

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs

Francis W. Hunter, Jagdish K. Jaiswal, Daniel G. Hurley, H. D. Sarath Liyanage, Sarah P. McManaway, Yongchuan Gu, Susan Richter, Jingli Wang, Moana Tercel, Cristin G. Print, William R. Wilson, Frederik B. Pruijn

BIOCHEMICAL PHARMACOLOGY (2014)

Article Pharmacology & Pharmacy

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

Stephen M. F. Jamieson, Yongchuan Gu, Donya Moradi Manesh, Jad El-Hoss, Duohui Jing, Karen L. MacKenzie, Christopher P. Guise, Annika Foehrenbacher, Susan M. Pullen, Juliana Benito, Jeffrey B. Smaill, Adam V. Patterson, Medhanie A. Mulaw, Marina Konopleva, Stefan K. Bohlander, Richard B. Lock, William R. Wilson

BIOCHEMICAL PHARMACOLOGY (2014)

Article Biochemistry & Molecular Biology

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers

Muriel Bonnet, Cho Rong Hong, Yongchuan Gu, Robert F. Anderson, William R. Wilson, Frederik B. Pruijn, Jingli Wang, Kevin O. Hicks, Michael P. Hay

BIOORGANIC & MEDICINAL CHEMISTRY (2014)

Article Oncology

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Mark J. McKeage, Michael B. Jameson, Ramesh K. Ramanathan, Joseph Rajendran, Yongchuan Gu, William R. Wilson, Teresa J. Melink, N. Simon Tchekmedyian

BMC CANCER (2012)

Article Pharmacology & Pharmacy

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1

Guanyu Lin, Renhua Gai, Zibo Chen, Yijie Wang, Sida Liao, Rong Dong, Hong Zhu, Yongchuan Gu, Qiaojun He, Bo Yang

EUROPEAN JOURNAL OF PHARMACOLOGY (2014)

Article Biochemistry & Molecular Biology

Zinc Finger Nuclease Knock-out of NADPH: Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

Jiechuang Su, Yongchuan Gu, Frederik B. Pruijn, Jeff B. Smaill, Adam V. Patterson, Christopher P. Guise, William R. Wilson

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

Article Chemistry, Medicinal

Photodegradation of the Benzotriazine 1,4-Di-N-Oxide Hypoxia-Activated Prodrug SN30000 in Aqueous Solution

Yongchuan Gu, Jagdish K. Jaiswal, Jingli Wang, Kevin O. Hicks, Michael P. Hay, William R. Wilson

JOURNAL OF PHARMACEUTICAL SCIENCES (2014)

Article Pharmacology & Pharmacy

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361

Way Wua Wong, Rosanna K. Jackson, Lydia P. Liew, Benjamin D. Dickson, Gary J. Cheng, Barbara Lipert, Yongchuan Gu, Francis W. Hunter, William R. Wilson, Michael P. Hay

BIOCHEMICAL PHARMACOLOGY (2019)

No Data Available